Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

  • End date
    Dec 31, 2025
  • participants needed
  • sponsor
    Hannah Choe
Updated on 23 April 2022


This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor with a unique binding mode selective for BRD4 inhibition and a more tolerable side effect profile. PLX51107 may work better in treating steroid-refractory acute GVHD.



I. To evaluate the safety and tolerability of BRD4 inhibitor PLX51107 (PLX51107) as a single agent for allogeneic transplant recipients with steroid-refractory acute graft versus host disease (GVHD).

II. To assess the pharmacokinetic (PK) and pharmacodynamic (PD) of orally administered PLX51107 in steroid-refractory acute GVHD patients.


I. To evaluate the preliminary efficacy of PLX51107 in steroid-refractory acute GVHD patients.


Patients receive BRD4 inhibitor PLX51107 orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then up to 6 months.

Condition Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Treatment BRD4 Inhibitor PLX51107
Clinical Study IdentifierNCT04910152
SponsorHannah Choe
Last Modified on23 April 2022


Yes No Not Sure

Inclusion Criteria

Age >= 18 years at the time of signing informed consent
Steroid-refractory acute GVHD as defined as progression of acute (a)GvHD within 3-5 days of therapy onset with >= 2 mg/kg/day of prednisone equivalent OR failure to improve within 5-7 days of treatment initiation with > 1-2 mg/kg/day of prednisone equivalent OR incomplete response after more than 28 days of immunosuppressive treatment including steroids
Recipients of ablative and reduced-intensity conditioning regimens
Recipients of human leukocyte antigen (HLA)-matched related and unrelated, 1-allele mismatched, haploidentical, or umbilical cord blood donor grafts
Prior lines of therapy for treatment of steroid-refractory acute GVHD are allowed. However, exposure to investigational therapies for the treatment of GVHD must be > 14 days or 5 half-lives (whichever is shorter) of first administration of study drug. For patients treated with ruxolitinib for the treatment of acute GVHD, ruxolitinib must be discontinued by at least one day prior to initiation of PLX51107
Eastern Cooperative Oncology Group (ECOG) performance status =< 3
Absolute neutrophil count >= 1.0 x 10^9/L for 3 consecutive days). Use of growth factor support is allowed
Platelet count >= 50 x 10^9/L without transfusion support for 2 consecutive days
Women of child-bearing potential must have a negative serum pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for >= 1 year
Fertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug

Exclusion Criteria

Prior exposure to a bromodomain inhibitor
Evidence of chronic GVHD
Evidence of active relapse of disease
Exposure to other investigational or anti-cancer therapies (not for GVHD) within 28 days or 5 half-lives (whichever is shorter) of first administration of study drug
Active, uncontrolled bacterial, fungal, or viral infection
Known or suspected allergy to the study drug
Clinically significant cardiac disease, defined as
Clinically significant cardiac arrhythmias, including bradyarrhythmia, and/or a need for anti-arrhythmic therapy (excluding beta blockers or digoxin). Individuals with controlled atrial fibrillation are not excluded
Fridericia-corrected QT interval (QTcF) >= 450 ms (male) or >= 470 ms (female) at screening
History of clinically significant cardiac disease or congestive heart failure greater than New York Heart Association Class II. Subjects must not have unstable angina (angina symptoms at rest) or experienced either new-onset angina within the last 3 months or myocardial infarction (MI) within the last 6 months unless it was due to the underlying disease and there has been appropriate revascularization. Individuals with ambiguous troponin levels that are not diagnostic of an MI should be discussed with the principal investigator (PI) prior to enrollment
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the 6 months before start of study medication (except for catheter-related venous thrombosis
Inability to take oral medication or significant nausea and vomiting, malabsorption
or significant small bowel resection that, in the opinion of the Investigator
would preclude adequate absorption
Active thrombotic microangiopathy (TMA)
Women who are either pregnant or breast feeding
Measured or calculated (Cockcroft-Gault formula) creatinine clearance (CrCl) < 45 mL/min
Prothrombin time or international normalized ratio > 1.5 x upper limit of normal (ULN)
Activated partial thromboplastin time > 1.5 x ULN
Requiring mechanical ventilation or vasopressor support
Subject is participating in any other therapeutic clinical study (observational or registry studies are allowed)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note